4.1 Article

Cost-Utility Analysis of Anterior Cervical Discectomy and Fusion With Plating (ACDFP) Versus Posterior Cervical Foraminotomy (PCF) for Patients With Single-level Cervical Radiculopathy at 1-Year Follow-up

Journal

CLINICAL SPINE SURGERY
Volume 29, Issue 2, Pages E67-E72

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BSD.0000000000000099

Keywords

cost-effectiveness; comparative effectiveness; QALY; ACDF; PCF; cervical fusion

Ask authors/readers for more resources

Study Design: A retrospective 1-year cost-utility analysis. Objective: To determine the cost-effectiveness of anterior cervical discectomy and fusion with plating (ACDFP) in comparison with posterior cervical foraminotomy (PCF) for patients with single-level cervical radiculopathy. Summary of Background Data: Cervical radiculopathy due to cervical spondylosis is commonly treated by either PCF or ACDFP for patients who are refractory to nonsurgical treatment. Although some have suggested superior outcomes with ACDFP as compared with PCF, the former is also associated with greater costs. The present study analyzes the cost-effectiveness of ACDFP versus PCF for patients with single-level cervical radiculopathy. Methods: Forty-five patients who underwent ACDFP and 25 patients who underwent PCF for single-level cervical radiculopathy were analyzed. One-year postoperative health outcomes were assessed based on Visual Analogue Scale, Pain Disability Questionnaire, Patient Health Questionnaire, and EuroQOL-5 Dimensions questionnaires to analyze the comparative effectiveness of each procedure. Direct medical costs were estimated using Medicare national payment amounts and indirect costs were based on patient missed work days and patient income. Postoperative 1-year cost/utility ratios and the incremental cost-effectiveness ratio (ICER) were calculated to assess for cost-effectiveness using a threshold of $ 100,000/QALY gained. Results: The 1-year cost-utility ratio for the PCF cohort was significantly lower ($ 79,856/QALY gained) than that for the ACDFP cohort ($ 131,951/QALY gained) (P < 0.01). In calculating the 1-year ICER, as the ACDFP cohort showed lower QALY gained than the PCF cohort, the ICER was negative and is not reported, meaning that ACDFP was dominated by PCF. Conclusions: Statistically significant and clinically relevant improvements (through minimum clinically important differences) were seen in both cohorts. Although both cohorts showed improved health outcomes, ACDFP was not cost-effective relative to the threshold of $ 100,000/QALY gained at 1-year post-operatively, whereas PCF was. The durability of these results must be analyzed with long-term cost-utility analysis studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Clinical Neurology

Neurological outcomes following awake and asleep craniotomies with motor mapping for eloquent tumor resection

Joshua Kurian, Mark N. Pernik, Jeffrey Traylor, William H. Hicks, Mohamad El Shami, Kalil G. Abdullah

Summary: This study reviewed articles describing cortical mapping for tumor resection in the past 20 years and evaluated the contribution of awake versus asleep cortical mapping to postoperative neurological deficits. The findings showed similar rates of transient and permanent neurological deficits between awake and asleep cortical mapping groups.

CLINICAL NEUROLOGY AND NEUROSURGERY (2022)

Article Oncology

Establishment of patient-derived organoid models of lower-grade glioma

Kalil G. Abdullah, Cylaina E. Bird, Joseph D. Buehler, Lauren C. Gattie, Milan R. Savani, Alex C. Sternisha, Yi Xiao, Michael M. Levitt, William H. Hicks, Wenhao Li, Denise M. O. Ramirez, Toral Patel, Tomas Garzon-Muvdi, Samuel Barnett, Gao Zhang, David M. Ashley, Kimmo J. Hatanpaa, Timothy E. Richardson, Samuel K. McBrayer

Summary: An optimized protocol was developed to establish organoids from LGG primary tissue samples, producing the first suite of these models. Patient-derived organoids recapitulated key biological features of their respective parental tumor specimens, demonstrating fidelity and potential for preclinical studies and personalized treatment assessments.

NEURO-ONCOLOGY (2022)

Article Oncology

Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas

Shiyou Wei, Delong Yin, Shengnan Yu, Xiang Lin, Milan R. Savani, Kuang Du, Yin Ku, Di Wu, Shasha Li, Hao Liu, Meng Tian, Yaohui Chen, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Stephen T. Keir, Eric T. Sugarman, Rebecca A. Deek, Marilyne Labrie, Mustafa Khasraw, Yiling Lu, Gordon B. Mills, Meenhard Herlyn, Kongming Wu, Lunxu Liu, Zhi Wei, Keith T. Flaherty, Kalil Abdullah, Gao Zhang, David M. Ashley

Summary: This study aimed to investigate the antitumor activity and mechanisms of a mitochondrial-localized HSP90 inhibitor, Gamitrinib, in multiple glioma models. The results showed that Gamitrinib inhibited cell proliferation, induced apoptosis and delayed tumor growth in glioma cell lines and animal models. Integrated analysis revealed that Gamitrinib acted by suppressing mitochondrial biogenesis and tumor bioenergetics, and activating related pathways.

CLINICAL CANCER RESEARCH (2022)

Article Neurosciences

Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas

Yan Liu, Adwait Amod Sathe, Kalil G. Abdullah, Samuel K. McBrayer, Steven H. Adams, Andrew J. Brenner, Kimmo J. Hatanpaa, Mariano S. Viapiano, Chao Xing, Jamie M. Walker, Timothy E. Richardson

Summary: This study used global methylation profiling to identify the presence/absence of chromosomal instability (CIN) in IDH-mutant astrocytomas. It was found that IDH-mutant astrocytomas with evidence of CIN have distinct characteristics and worse clinical outcomes compared to chromosomally stable counterparts.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2022)

Article Cell Biology

EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation

Gao Guo, Ke Gong, Nicole Beckley, Yue Zhang, Xiaoyao Yang, Rati Chkheidze, Kimmo J. Hatanpaa, Tomas Garzon-Muvdi, Prasad Koduru, Arifa Nayab, Jennifer Jenks, Adwait Amod Sathe, Yan Liu, Chao Xing, Shwu-Yuan Wu, Cheng-Ming Chiang, Bipasha Mukherjee, Sandeep Burma, Bryan Wohlfeld, Toral Patel, Bruce Mickey, Kalil Abdullah, Michael Youssef, Edward Pan, David E. Gerber, Shulan Tian, Jann N. Sarkaria, Samuel K. McBrayer, Dawen Zhao, Amyn A. Habib

Summary: In this study, the authors discovered a new tumor-suppressive function of EGFR in EGFR-amplified glioblastomas. They found that the level of EGFR ligands can shift the role of EGFR from an oncogene to a tumor suppressor, influencing the prognosis of the disease. Increasing the level of EGFR ligands can activate the tumor-suppressive function of EGFR, resulting in inhibited tumor growth and invasion.

NATURE CELL BIOLOGY (2022)

Review Neurosciences

Chromosomal instability in adult-type diffuse gliomas

Timothy E. Richardson, Jamie M. Walker, Kalil G. Abdullah, Samuel K. McBrayer, Mariano S. Viapiano, Zarmeen M. Mussa, Nadejda M. Tsankova, Matija Snuderl, Kimmo J. Hatanpaa

Summary: Chromosomal instability (CIN) is a fundamental property of cancer and a key mechanism of tumorigenesis and progression. It is found in various cancers and is associated with poor clinical outcomes. However, there have been relatively few studies on this process, mainly due to the difficulty of measuring it clinically.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2022)

Article Clinical Neurology

Surgical Management of a Massive Frontal Bone Hemangioma: Case Report

Cylaina E. Bird, Jeffrey I. Traylor, Zachary D. Johnson, Jun Kim, Jack Raisanen, Babu G. Welch, Kalil G. Abdullah

Summary: Intraosseous hemangiomas are rare benign tumors that can invade the outer table of the skull but typically spare the inner layer and intracranial structures. Surgical resection is the standard treatment, with proper reconstruction critical for cosmetic outcomes. En bloc or piecemeal resection may be necessary depending on the extent of involvement.

JOURNAL OF NEUROLOGICAL SURGERY REPORTS (2022)

Article Oncology

De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma

Diana D. Shi, Milan R. Savani, Michael M. Levitt, Adam C. Wang, Jennifer E. Endress, Cylaina E. Bird, Joseph Buehler, Sylwia A. Stopka, Michael S. Regan, Yu-Fen Lin, Vinesh T. Puliyappadamba, Wenhua Gao, Januka Khanal, Laura Evans, Joyce H. Lee, Lei Guo, Yi Xiao, Min Xu, Bofu Huang, Rebecca B. Jennings, Dennis M. Bonal, Misty S. Martin-Sandoval, Tammie Dang, Lauren C. Gattie, Amy B. Cameron, Sungwoo Lee, John M. Asara, Harley I. Kornblum, Tak W. Mak, Ryan E. Looper, Quang-De Nguyen, Sabina Signoretti, Stefan Gradl, Andreas Sutter, Michael Jeffers, Andreas Janzer, Mark A. Lehrman, Lauren G. Zacharias, Thomas P. Mathews, Julie-Aurore Losman, Timothy E. Richardson, Daniel P. Cahill, Ralph J. DeBerardinis, Keith L. Ligon, Lin Xu, Peter Ly, Nathalie Y. R. Agar, Kalil G. Abdullah, Isaac S. Harris, William G. Kaelin, Samuel K. McBrayer

Summary: This study found that IDH1-mutant glioma cells are hypersensitive to drugs targeting enzymes in the de novo pyrimidine nucleotide synthesis pathway. They also showed that a brain-penetrant DHODH inhibitor exhibits monotherapy efficacy against IDH-mutant gliomas, based on experiments using a genetically engineered mouse model and patient-derived models.

CANCER CELL (2022)

Review Oncology

DNA damage in IDH-mutant gliomas: mechanisms and clinical implications

Diana D. Shi, Soummitra Anand, Kalil G. Abdullah, Samuel K. McBrayer

Summary: This article summarizes the current understanding of how IDH mutations influence DNA damage in glioma and discusses the clinical implications of these findings.

JOURNAL OF NEURO-ONCOLOGY (2023)

Article Oncology

Semi-Automated Computational Assessment of Cancer Organoid Viability Using Rapid Live-Cell Microscopy

Joseph D. Buehler, Cylaina E. Bird, Milan R. Savani, Lauren C. Gattie, William H. Hicks, Michael M. Levitt, Mohamad El Shami, Kimmo J. Hatanpaa, Timothy E. Richardson, Samuel K. McBrayer, Kalil G. Abdullah

Summary: The researchers established a set of 3-dimensional patient-derived glioma organoids and developed a new algorithm to evaluate organoid viability. They found correlations between the new algorithm and traditional markers of cell viability, providing a quantitative measurement of organoid viability.

CANCER INFORMATICS (2022)

Meeting Abstract Oncology

A METHOD FOR EX VIVO STABLE ISOTOPE TRACING IN SURGICALLY EXPLANTED GLIOMA ORGANOIDS

Mohamad El Shami, Milan Savani, Lauren Gattie, William Hicks, Timothy Richardson, Samuel McBrayer, Kalil Abdullah

NEURO-ONCOLOGY (2022)

Meeting Abstract Clinical Neurology

TERT promoter mutations are rare in IDH-mutant astrocytomas and have an adverse impact on survival

Timothy Richardson, Steven Adams, Kimmo Hatanpaa, Andrea Gilbert, Samuel McBrayer, Kalil Abdullah, Andrew Brenner, Jamie Walker

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2022)

Meeting Abstract Clinical Neurology

Oligodendroglioma with Recurrence as Glioblastoma: Concordant Histologic Features and Discordant Molecular Findings

Neda Wick, Changhong Xing, Yanel De Los Santos, Kalil Abdullah, Michael Youssef, Elena Daoud, Jack Raisanen, Kimmo Hatanpaa

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2022)

Article Cell & Tissue Engineering

Creation and Development of Patient-Derived Organoids for Therapeutic Screening in Solid Cancer

William H. Hicks, Cylaina E. Bird, Lauren C. Gattie, Mohamad El Shami, Jeffrey Traylor, Diana D. Shi, Samuel K. McBrayer, Kalil G. Abdullah

Summary: Personalized cancer therapy requires accurate cancer models, and patient-derived organoids offer a promising approach. These organoids retain the heterogeneity of tumors and demonstrate similar therapeutic responsiveness, making them useful for drug screening and treatment selection.

CURRENT STEM CELL REPORTS (2022)

Meeting Abstract Oncology

Identification of De Novo Pyrimidine Synthesis as a Targetable Vulnerability in a Novel IDH1 Mutant Engineered Astrocytoma Model

D. D. Shi, A. C. Wang, W. Gao, J. Khanal, M. M. Levitt, R. B. Jennings, S. Signoretti, Q. D. Nguyen, J. E. Endress, M. Xu, S. Gradl, A. Sutter, M. Jeffers, A. Janzer, D. P. Cahill, K. G. Abdullah, K. L. Ligon, I. S. Harris, W. G. Kaelin, S. K. McBrayer

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

No Data Available